^
Association details:
| Biomarker: | MSI-H/dMMR + MLH1 negative + PMS2 negative |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Salvage Treatment Using Anti–PD-1/CTLA-4 Immunotherapy After Failure of Neoadjuvant Chemotherapy in Microsatellite Instable Gastroesophageal Carcinoma
Published date:
04/15/2021
Excerpt:
...biopsies demonstrated a poorly differentiated adenocarcinoma with immunohistochemistry revealing a loss of MLH-1 and PMS-2 expression in keeping with an MSI-H phenotype...In view of the MSI-high tumor status, the patient subsequently commenced combination...nivolumab...and...ipilimumab....The patient has subsequently undergone a repeat gastroscopy with biopsies of the residual tumor mass revealing no malignant cells and extensive inflammatory changes...
DOI:
https://doi.org/10.1002/onco.13793
